Pirfenidone: Extent of added benefit assessed
Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since the beginning of 2011. ...
Jan 3, 2012
0
0